EZH2 and lymphoma: Recent sequencing studies have identified numerous mutations of EZH2 in a variety of leukemias and lymphomas, including follicular lymphoma (FL; 7%–22%), diffuse large B-cell lymphoma (DLBCL; 14%–21.7%), high grade B-cell lymphoma (18%), MDS/MPN (6%–13%), CMML (11.1%), T-ALL, and AML (Abdel-Wahab et al., 2011; Bodor et al., 2011; Capello et al., 2011; Ernst et al., 2010; Grossmann et al., 2011; Lohr et al., 2012; Makishima et al., 2010; Morin et al., 2010; Nikoloski et al., 2010; Ryan et al., 2011; Zhang et al., 2012).